131 related articles for article (PubMed ID: 33422541)
1. Inhibition of striatal dopamine D
Wang Y; Yao L; Gao S; Zhang G; Zhang Q; Liu W; Zhou Y; Sun Y; Feng J; Liu J
Brain Res; 2021 Mar; 1754():147266. PubMed ID: 33422541
[TBL] [Abstract][Full Text] [Related]
2. Striatal D
Gao S; Gao R; Yao L; Feng J; Liu W; Zhou Y; Zhang Q; Wang Y; Liu J
Front Aging Neurosci; 2022; 14():783893. PubMed ID: 35185524
[TBL] [Abstract][Full Text] [Related]
3. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
4. The Dynamics of Dopamine D
Liu K; Song M; Gao S; Yao L; Zhang L; Feng J; Wang L; Gao R; Wang Y
Neurosci Bull; 2023 Sep; 39(9):1411-1425. PubMed ID: 37022638
[TBL] [Abstract][Full Text] [Related]
5. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Wang Y; Wang HS; Wang T; Huang C; Liu J
J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
[TBL] [Abstract][Full Text] [Related]
6. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
[TBL] [Abstract][Full Text] [Related]
7. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
Mela F; Marti M; Bido S; Cenci MA; Morari M
Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of striatal Ca
Caulfield ME; Vander Werp MJ; Stancati JA; Collier TJ; Sortwell CE; Sandoval IM; Manfredsson FP; Steece-Collier K
Neurobiol Dis; 2023 Jun; 181():106111. PubMed ID: 37001610
[TBL] [Abstract][Full Text] [Related]
9. Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Yang X; Chen Y; Hong X; Wu N; Song L; Yuan W; Liu Z
Drug Des Devel Ther; 2012; 6():341-7. PubMed ID: 23185117
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
11. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
12. Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Zheng C; Xu Y; Chen G; Tan Y; Zeng W; Wang J; Cheng C; Yang X; Nie S; Zhang Z; Cao X
Neurobiol Dis; 2020 Jun; 139():104807. PubMed ID: 32088382
[TBL] [Abstract][Full Text] [Related]
13. Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
Monville C; Torres EM; Dunnett SB
Brain Res Bull; 2005 Dec; 68(1-2):16-23. PubMed ID: 16325000
[TBL] [Abstract][Full Text] [Related]
14. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
15. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the differential roles of striatal 5-HT
Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
[TBL] [Abstract][Full Text] [Related]
17. NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.
Wu N; Song L; Yang X; Yuan W; Liu Z
Clin Interv Aging; 2013; 8():347-52. PubMed ID: 23569367
[TBL] [Abstract][Full Text] [Related]
18. Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Tohge R; Kaneko S; Morise S; Oki M; Takenouchi N; Murakami A; Nakamura M; Kusaka H; Yakushiji Y
Neuropharmacology; 2021 Oct; 198():108771. PubMed ID: 34474045
[TBL] [Abstract][Full Text] [Related]
19. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Dupre KB; Ostock CY; Eskow Jaunarajs KL; Button T; Savage LM; Wolf W; Bishop C
Exp Neurol; 2011 Jun; 229(2):288-99. PubMed ID: 21352823
[TBL] [Abstract][Full Text] [Related]
20. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
